Organogenesis Holdings Inc
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barrier… Read more
Organogenesis Holdings Inc (ORGO) - Net Assets
Latest net assets as of September 2025: $385.98 Million USD
Based on the latest financial reports, Organogenesis Holdings Inc (ORGO) has net assets worth $385.98 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($509.83 Million) and total liabilities ($123.85 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $385.98 Million |
| % of Total Assets | 75.71% |
| Annual Growth Rate | N/A |
| 5-Year Change | 171.72% |
| 10-Year Change | N/A |
| Growth Volatility | 63.64 |
Organogenesis Holdings Inc - Net Assets Trend (2001–2024)
This chart illustrates how Organogenesis Holdings Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Organogenesis Holdings Inc (2001–2024)
The table below shows the annual net assets of Organogenesis Holdings Inc from 2001 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $385.32 Million | +38.27% |
| 2023-12-31 | $278.66 Million | +4.89% |
| 2022-12-31 | $265.67 Million | +10.08% |
| 2021-12-31 | $241.34 Million | +70.18% |
| 2020-12-31 | $141.81 Million | +155.13% |
| 2019-12-31 | $55.58 Million | +18.16% |
| 2018-12-31 | $47.04 Million | -84.22% |
| 2017-12-31 | $298.01 Million | -0.70% |
| 2016-12-31 | $300.11 Million | +185251674.69% |
| 2015-12-31 | $-162.00 | +99.99% |
| 2001-12-31 | $-2.08 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Organogenesis Holdings Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2211910708.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $13.00K | 0.00% |
| Other Components | $425.41 Million | 110.41% |
| Total Equity | $385.32 Million | 100.00% |
Organogenesis Holdings Inc Competitors by Market Cap
The table below lists competitors of Organogenesis Holdings Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
C C Land Holdings Limited
PINK:CCLHF
|
$141.49 Million |
|
Gérard Perrier Industrie S.A
PA:PERR
|
$141.51 Million |
|
H+H International A/S
CO:HH
|
$141.52 Million |
|
Bemobi Mobile Tech S.A
SA:BMOB3
|
$141.55 Million |
|
ZRP Printing Group Co. Ltd.
SHE:301223
|
$141.29 Million |
|
Shenzhen Magic Design & Decoration Engineering Co Ltd
SHE:002856
|
$141.27 Million |
|
Dhani Services Limited
NSE:DHANI
|
$141.20 Million |
|
Ina Invest Holding AG
SW:INA
|
$141.20 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Organogenesis Holdings Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 278,663,000 to 385,316,000, a change of 106,653,000 (38.3%).
- Net income of 861,000 contributed positively to equity growth.
- Dividend payments of 1,798,000 reduced retained earnings.
- Share repurchases of 25,479,000 reduced equity.
- New share issuances of 120,688,000 increased equity.
- Other factors increased equity by 12,381,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $861.00K | +0.22% |
| Dividends Paid | $1.80 Million | -0.47% |
| Share Repurchases | $25.48 Million | -6.61% |
| Share Issuances | $120.69 Million | +31.32% |
| Other Changes | $12.38 Million | +3.21% |
| Total Change | $- | 38.27% |
Book Value vs Market Value Analysis
This analysis compares Organogenesis Holdings Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.86x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $0.00 | $2.53 | x |
| 2016-12-31 | $34.98 | $2.53 | x |
| 2017-12-31 | $4.67 | $2.53 | x |
| 2018-12-31 | $0.68 | $2.53 | x |
| 2019-12-31 | $0.60 | $2.53 | x |
| 2020-12-31 | $1.27 | $2.53 | x |
| 2021-12-31 | $1.81 | $2.53 | x |
| 2022-12-31 | $2.01 | $2.53 | x |
| 2023-12-31 | $2.10 | $2.53 | x |
| 2024-12-31 | $2.93 | $2.53 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Organogenesis Holdings Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.22%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.18%
- • Asset Turnover: 0.97x
- • Equity Multiplier: 1.29x
- Recent ROE (0.22%) is above the historical average (-13.56%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2001 | 0.00% | -276.55% | 0.40x | 0.00x | $-2.67 Million |
| 2015 | 0.00% | -0.03% | 237.77x | 0.00x | $-25.14K |
| 2016 | -0.07% | 0.00% | 0.00x | 1.04x | $-30.22 Million |
| 2017 | -0.70% | 0.00% | 0.00x | 1.05x | $-31.90 Million |
| 2018 | -137.82% | -33.51% | 1.18x | 3.48x | $-69.54 Million |
| 2019 | -69.64% | -14.83% | 1.18x | 3.97x | $-44.27 Million |
| 2020 | 12.15% | 5.09% | 1.17x | 2.05x | $3.05 Million |
| 2021 | 39.03% | 20.16% | 1.05x | 1.84x | $70.07 Million |
| 2022 | 5.85% | 3.44% | 1.00x | 1.69x | $-11.03 Million |
| 2023 | 1.77% | 1.14% | 0.94x | 1.65x | $-22.92 Million |
| 2024 | 0.22% | 0.18% | 0.97x | 1.29x | $-37.67 Million |
Industry Comparison
This section compares Organogenesis Holdings Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Organogenesis Holdings Inc (ORGO) | $385.98 Million | 0.00% | 0.32x | $141.43 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |